Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor

World Journal of Gastroenterology

Volumn 19, Issue 8, 2013, Pages 1318-1321

  Lai, Guan Min ^a   Yan, Sheng Lei ^b   Chang, Cheng Shyong ^a   Tsai, Chien Yu ^a  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b SHOW CHWAN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Chronic myeloid leukemia; Hepatitis B virus; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B (E) ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; ECHOGRAPHY; FATIGUE; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; JAUNDICE; LEUKOCYTOSIS; LIVER INJURY; MALE; PHILADELPHIA 1 CHROMOSOME; RECURRENT DISEASE; SIDE EFFECT; THROMBOCYTOSIS; URINE COLOR;

EID: 84874622931     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i8.1318     Document Type: Article

References (24)

1. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307 [PMID: 11055239 DOI: 10.1002/1096-9071(200011)62:]
2. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, Lam KC, Johnson PJ. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311 [PMID: 15054446 DOI: 10.1038/ sj.bjc.6601699]
3. Xunrong L, Yan AW, Liang R, Lau GK. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management. Rev Med Virol 2001; 11: 287-299 [PMID: 11590667 DOI: 10.1002/rmv.322]
4. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008; 22: 117-126 [PMID: 18343002 DOI: 10.1016/j.blre.2008.02.001]
5. Jabbour E, Fava C, Kantarjian H. Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Pract Res Clin Haematol 2009; 22: 395-407 [PMID: 19959090 DOI: 10.1016/j.beha.2009.09.002]
6. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566 [PMID: 8616716 DOI: 10.1038/nm0596-561]
7. Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y, Maruyama Y. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006; 47: 155-157 [PMID: 16321842 DOI: 10.1080/14639230500236818]
8. Thia TJ, Tan HH, Chuah TH, Chow WC, Lui HF. Imatinib mesylaterelated fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J 2008; 49: e86-e89 [PMID: 18362995]
9. Lakhani S, Davidson L, Priebat DA, Sherker AH. Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy. Hepatol Int 2008; 2: 498-499 [PMID: 19669326 DOI: 10.1007/s12072-008-9099-5]
10. Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, Hwang YJ, Sohn SK. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009; 90: 383-387 [PMID: 19641858 DOI: 10.1007/s12185-009-0386-2]
11. Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ. Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc 2010; 42: 843-845 [PMID: 20430187 DOI: 10.1016/j.trans proceed.2010.02.038]
12. Wang YD, Cui GH, Li M, Gowrea B, Xia J, Hu Y. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J (Engl) 2012; 125: 2636-2637 [PMID: 22882953]
13. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220 [PMID: 16440366 DOI: 10.1002/ hep.21051]
14. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935-942 [PMID: 12006504]
15. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, Kimura Y, Serizawa H, Ebihara Y. Imatinib mesylateinduced hepatotoxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2002; 16: 2160-2161 [PMID: 12357373 DOI: 10.1038/sj.leu.2402702]
16. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003; 17: 978-979 [PMID: 12750713 DOI: 10.1038/sj.leu.2402910]
17. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF. Imatinib (Gleevec)-induced hepatotoxicity. J Clin Gastroenterol 2005; 39: 75-77 [PMID: 15599217]
18. Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, Nagai T, Mori M, Komatsu N, Ozawa K. Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes. Leuk Lymphoma 2004; 45: 2349-2351 [PMID: 15512829 DOI: 10.1080/10428190 412331272721]
19. Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptormediated T-cell proliferation and activation in a dosedependent manner. Blood 2005; 105: 2473-2479 [PMID: 15572591 DOI: 10.1182/blood-2004-07-2527]
20. Cwynarski K, Laylor R, Macchiarulo E, Goldman J, Lombardi G, Melo JV, Dazzi F. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332-1339 [PMID: 15190258 DOI: 10.1038/ sj.leu.2403401]
21. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394-398 [PMID: 10458258]
22. Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mandó OG. Imatinibinduced fatal acute liver failure. World J Gastroenterol 2007; 13: 6608-6111 [PMID: 18161937]
23. Mohty M, Jourdan E, Mami NB, Vey N, Damaj G, Blaise D, Isnardon D, Olive D, Gaugler B. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood 2004; 103: 4666-4668 [PMID: 14715630 DOI: 10.1182/blood-2003-09-3220]
24. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]